Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 10.5.2022 | EN | Official Journal of the European Union | C 191/26 |

---

Judgment of the General Court of 2 March 2022 — VeriGraft v Eismea

(Case T-688/19) [(1)](#ntr1-C_2022191EN.01002601-E0001)

(Arbitration clause - Grant agreement concluded in the context of the ‘Horizon 2020’ Framework Programme for Research and Innovation - Termination of the agreement - Misconduct - Capacity as beneficiary of the grant or as a natural person acting in his or her name or on his or her behalf)

(2022/C 191/34)

Language of the case: English

Parties

Applicant: VeriGraft AB (Gothenburg, Sweden) (represented by: P. Hansson and A. Johansson, lawyers)

Defendant: European Innovation Council and SMEs Executive Agency (represented by: A. Galea, acting as Agent, and by D. Waelbroeck and A. Duron, lawyers)

Re:

Application based on Article 272 TFEU seeking a declaration of invalidity of the termination by the Executive Agency for Small and Medium-sized Enterprises (EASME) of the grant agreement concerning the project ‘Personalised Tissue Engineered Veins as the first Cure for Patients with Chronic Venous Insufficiency — P TEV’, concluded in the context of the instrument to support innovation in small and medium-sized enterprises of Horizon 2020 — the Framework Programme for Research and Innovation (2014-2020).

Operative part of the judgment

The Court:

|  |  |
| --- | --- |
| 1. | Declares that the termination by the Executive Agency for Small and Medium-sized Enterprises of the grant agreement for the project ‘Personalised Tissue Engineered Veins as the first Cure for Patients with Chronic Venous Insufficiency — P-TEV’, bearing reference 778620, is invalid; |

|  |  |
| --- | --- |
| 2. | Orders the European Innovation Council and SMEs Executive Agency to pay the costs. |

---

---

[Top](#document1)